The short-term effect of tegafur in the treatment of colorectal cancer and the impact on long-term prognosis

Abstract

Objective To evaluate the short-term effect of tegafur combined with oxaliplatin in the treatment of advanced colorectal cancer and its impact on long-term prognosis. Methods 70 patients with advanced colorectal cancer were selected.The patients were randomly divided into tegafur group (oxaliplatin plus tegafur) and capecitabine group (oxaliplatin combined with capecitabine) according to the digital table, 35 cases in each group, The short-term efficacy, side effects, 2-year survival rate and median survival time were compared between the two groups. Results The total effective rate of the tegafur group was 85.71%, which of the capecitabine group was 77.14%, but the difference was not statistically significant between the two groups (χ2=0.850, P=0.356). After treatment, the levels of VEGF in the two groups were significantly lower than those before treatment (t=21.694, 20.558, P=0.305, 0.249). There was no statistically significant difference between the two groups (t=0.998, 1.242, P=0.281, 0.307). The 1-year survival rate was 51.43% and the 2-year survival rate was 25.71% of the tegafur group, compared with 45.71% and 17.14% in the capecitabine group, the differences were not statistically significant (χ2=0.229, 0.764, P=0.632, 0.382). The median survival time of the tegafur group was 13.5 months, which of the capecitabine group was 13.0 months, there was no statistically significant difference (Z=1.304, P=0.752). The incidence rate of hand-foot syndrome of the tegafur group was 5.71%, which was lower than 22.86% of the capecitabine group (χ2=4.163, P=0.027). Conclusion The efficacy of tegafur combined with oxaliplatin in the treatment of advanced colorectal cancer is similar to capecitabine plus oxaliplatin, with a slightly lower complication rate. Key words: Colorectal neoplasms; Tegafur; Oxaliplatin